BIIB
Aims: This is a 72 week multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of BIIB023 in subjects with newly diagnosed lupus nephritis.
Diagnosis: Lupus Nephritis
Principal Investigator: Neenoo Khosla, MD
IRB Approval Number: EH 12-364
Sponsor: Biogen Idec
Contact: For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email Shonny Fettman at sfettman@northshore.org
Open to Enrollment: Yes
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Natural History Registry for Patients with Chronic Hypoparathyroidism
Aims: This is a 10 year registry study for patients with chronic hypoparathyroidism. The data collected may help doctors understand hypoparathyroidism better and help patients to make informed decisions about their treatment.
The purpose of this study is to collect medical information & to learn more about chronic hypoparathyroidism. Information collected will be used to study such variables as treatment of the disease, clinical outcomes, comorbidities and mortality in patients.
Participation in this study includes baseline visit and 1 follow-up visit every year for 10 years.
Diagnosis: Chronic Hypoparathyroidism
Principal Investigator: Stuart Sprague, DO
IRB Approval Number: EH 14-112
Sponsor: NPS
Contact: For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email srao@northshore.org
Open to Enrollment: Yes
Racial Differences in Proximal Tubule Function and Renal Hemodynamics in Chronic Kidney Disease
Aims: The purpose of this study is to compare differences in how healthy subjects and those with kidney disease handle blood flow and electrolytes. This study will include blood and urine tests, an IVC and infusions of tracer drugs to assess the clearance of these drugs. Participation in this study includes two study visits: One visit at NorthShore University HealthSystem Nephrology Research Office and one visit which will take place over 6 hours at the CTC at the University of Chicago.
Diagnosis:Chronic Kidney Disease
Principal Investigator: Stuart M. Sprague, DO
IRB Approval Number: EH 13-158
Sponsor: Investigator initiated
Contact: For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email sfettman@northshore.org
Open to Enrollment: Yes
SONAR
Aims: This is a Phase 111, randomized, double-blind, placebo controlled, parallel group trial to study the effect of Atrasentan on renal outcomes in subjects with type 2 diabetes and nephropathy. The purpose of this study is to see if Atrasentan, an oral drug, can slow the progression of kidney disease.
Diagnosis: Chronic Kidney Disease, not on dialysis
Principal Investigator: Menaka Sarav, MD
IRB Approval Number: EH 13-259
Sponsor: Abbvie
Contact: For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email Shonny Fettman at sfettman@northshore.org
Open to Enrollment: Yes
START: Strategies Using Darpepoetin alfa to Avoid Transfusions in Chronic Kidney Disease
Aims: This is a two year study comparing two different dosing strategies using Aranesp for the treatment of anemia in patients with Chronic Kidney Disease.
Diagnosis: Anemia; Chronic Kidney Disease
Principal Investigator: Stuart Sprague, DO
IRB Approval Number: EH 12-235
Sponsor: Amgen Inc
Contact: For more information, interested participants and clinicians may contact the Nephrology Research Office at 847.570.1761 or email Shonny Fettman at sfettman@northshore.org
Open to Enrollment: Yes